Isolate Data
| Patient | Isolate | Region | Year | Species | Subtype | Source | Clone Method |
| pt-G | ptGW16 | U.S. | 1996 | HIV1 | B | PBMC | MMC |
Treatment History
| Order | Regimen | Weeks |
| 1 | IDV | 16 |
Protease Sequence
| PIMajorDRMs | PIMinorDRMs | Polys | UnusualMuts |
| V32I, V82A | I15V, E35D, M36I, L63P, A71V |
| >ptGW16| 8 | codons 1-99 | clone 8 PQITLWQRPLVTIKVGGQLKEALLDTGADDTILEDINLPGRWKPKMIGGIGGFIKVRQYD QIPIEICGHKVIGTVLVGPTPANIIGRNLLTQIGCTLNF >ptGW16| 7 | codons 1-99 | clone 7 PQITLWQRPLVTIKVGGQLKEALLDTGADDTILEDINLPGRWKPKMIGGIGGFIKVRQYD QIPIEICGHKVIGTVLVGPTPANIIGRNLLTQIGCTLNF >ptGW16| 6 | codons 1-99 | clone 6 PQITLWQRPLVTIKVAGQLKEALLDTGADDTILEDINLPGRWKPKMIGGIGGFIKVRQYD QIPIEICGHKVIGTVLVGPTPANIIGRNLLTQIGCTLNF >ptGW16| 5 | codons 1-99 | clone 5 PQITLWQRPLVTIKVGGQLKEALLDTGADDTILEDINLPGRWKPKMIGGIGGFIKVRQYD QIPIEICGHKVIGTVLVGPTPANIIGRNLLTQIGCTLNF >ptGW16| 4 | codons 1-99 | clone 4 PQITLWQRPLVTIKVGGQLKEALLDTGADDTILEDINLPGRWKPKMIGGIGGFIKVRQYD QIPIEICGHKVIGTVLVGPTPANIIGRNLLTQIGCTLNF >ptGW16| 3 | codons 1-99 | clone 3 PQITLWQRPLVTIKVGGQLKEALLDTGADDTILEDINLPGRWKPKMIGGIGGFIKVRQYD QIPIEICGHKVIGTVLVGPTPANIIGRNLLTQIGCTLNF >ptGW16| 2 | codons 1-99 | clone 2 PQITLWQRPLVTIKVGGQLKEALLDTGADDTILEDINLPGRWKPKMIGGIGGFIKVRQYD QIPIEICGHKVIGTVLVGPTPANIIGRNLLTQIGCTLNF >ptGW16| 1 | codons 1-99 | clone 1 PQITLGQPPLVTIKVGGQLKEVLLDTGADDTILEDINLPGRWKPKMIGGIGGFIKVRQYD QIPIEICGHKVIGTVLVGPTPANIIGRNLLTQIGCTLNF >ptGW16| codons 1-99 PQITLWQRPLVTIKVGGQLKEALLDTGADDTILEDINLPGRWKPKMIGGIGGFIKVRQYD QIPIEICGHKVIGTVLVGPTPANIIGRNLLTQIGCTLNF |
References
| Author | Title | Citation |
| Condra, JH | Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. | J Virol, 1996 |
| Wu, TD | Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. | J Virol, 2003 |
| Rhee, SY | HIV-1 Protease and Reverse Transcriptase Mutations: Correlations with Antiretroviral Therapy in Subtype B Isolates and Implications for Drug-Resistance Surveillance. | J Infect Dis, 2005 |